Correspondence 0001683168-23-007169 from Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc.
Date: Oct. 13, 2023 · CIK: 0001367083 · Accession: 0001683168-23-007169
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274582
Referenced dates: September 27, 2023
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Registration Statement on Form S-1 Filed September 19, 2023 File No. 333-274582
Re: Sonoma Pharmaceuticals, Inc.
Dear Ms. Polynice:
I am the Chief Executive Officer for Sonoma Pharmaceuticals, Inc. (the “Company”). The Company will file a revised registration statement on Form S-1/A through EDGAR.
The Form S-1/A contains revisions that have been made in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in their letter dated September 27, 2023.
Set forth below is the Company’s responses to the Staff’s comments. The numbering of the responses corresponds to the numbering of the comment in the letter from the Staff.
Registration Statement on Form S-1 filed September 19, 2023
Cover Page
Comment 1:
Please revise your cover page to disclose the date the offering will end. Refer to
Item 501(b)(8)(iii) of Regulation S-K for guidance.
Response 1:
The Company has included a termination date for the offering of November 15, 2023, unless completed sooner or terminated prior to that date.
If you have further questions or comments, please feel free to contact me. I am happy to cooperate in any way I can.
Sincerely,
/s/ Amy Trombly
Show Raw Text
CORRESP
1
filename1.htm
October 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Cindy Polynice, Jason Drory
Re:
Sonoma Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed September 19, 2023
File No. 333-274582
Dear Ms. Polynice:
I am the Chief Executive Officer for Sonoma Pharmaceuticals, Inc. (the
“Company”). The Company will file a revised registration statement on Form S-1/A through EDGAR.
The Form S-1/A contains revisions that have been made in response to
comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) in
their letter dated September 27, 2023.
Set forth below is the Company’s responses to the Staff’s
comments. The numbering of the responses corresponds to the numbering of the comment in the letter from the Staff.
Registration Statement on Form S-1 filed September 19, 2023
Cover Page
Comment 1:
Please revise your cover page to disclose the date the offering will
end. Refer to
Item 501(b)(8)(iii) of Regulation S-K for guidance.
Response 1:
The Company has included a termination date for the offering of November
15, 2023, unless completed sooner or terminated prior to that date.
If you have further questions or comments, please feel free to contact
me. I am happy to cooperate in any way I can.
Sincerely,
/s/ Amy Trombly
Amy Trombly, Esq.